1
|
Azzouz JZ, Safdar OY, Awaleh FI, Khoja AA, Alattas AA, Jawhari AA. Nutritional Assessment and Management in Paediatric Chronic Kidney Disease. J Nutr Metab 2021; 2021:8283471. [PMID: 34676115 PMCID: PMC8526268 DOI: 10.1155/2021/8283471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Accepted: 10/07/2021] [Indexed: 11/17/2022] Open
Abstract
Nutrition in paediatrics has always been one of the most important factors for optimal growth. Children with chronic kidney disease (CKD) need special consideration for better long-term outcomes, including nutritional status, optimal height, and cognitive function. Nonetheless, there are many obstacles to overcome to attain optimal linear growth and nutritional status in children with CKD. This review highlights the need for tools to assess the growth parameters in CKD. In addition, recommendations for dietary intake play a major role in controlling electrolyte disturbances in patients with CKD. For example, it is still unclear whether it is better to restrict phosphate sources in inorganic, organic, or food additives. The review also summarises different factors such as fluid intake, route of feeding, and essential nutrients that require particular attention in paediatric patients with CKD. In summary, a multidisciplinary team is needed to devise individual nutritional plans to achieve the best outcome and improve the quality of life of patients.
Collapse
Affiliation(s)
| | - Osama Yousef Safdar
- Center of Excellence in Pediatric Nephrology, King Abdulaziz University, Jeddah, Saudi Arabia
| | | | | | | | | |
Collapse
|
2
|
Li M, Fan X, Mao Q, Li Q, Zhang X, He G, Zhang S, Zhang W. The hollow core-shell ferric oxide entrapped chitosan microcapsules as phosphate binders for phosphorus removal in vitro. Carbohydr Polym 2021; 257:117621. [PMID: 33541649 DOI: 10.1016/j.carbpol.2021.117621] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 01/02/2021] [Accepted: 01/03/2021] [Indexed: 11/24/2022]
Abstract
Patients in hyperphosphatemia are orally prescribed with phosphate binders to excrete the non-metabolic phosphorus. Aiming for the bio-compatibility and binding efficacy, the Fe-based phosphate binders of low toxicity have been explored and improved. Herein, the hollow core-shell microcapsules as Fe@CH (nano ferric oxide entrapped in the polymerized chitosan) were constructed via emulsion interface polymerization, to enhance the phosphate binding from -NH2 group and iron complex, and limit iron leakage significantly. Via the double emulsion polymerization based on the primary Pickering emulsion stabilized by oleic acid-modified ferric oxide, Fe@CH performed as the rough polymerized-chitosan microcapsules entrapping well-distributed ferric oxide for the phosphate adsorption in vitro. At pH 3 and pH 5, Fe@CH bound phosphorus efficiently, with the capacity of 55 mg/g and 65 mg/g respectively, along with the excellent shell isolation from iron leakage and remarkable safety. Prospectively, the Fe@CH micro-sorbent is the proper candidate as the phosphate binder for hyperphosphatemia.
Collapse
Affiliation(s)
- Min Li
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, 116023, China
| | - Xianlin Fan
- School of Chemical Engineering, Dalian University of Technology, Panjin, 124221, China
| | - Qian Mao
- School of Chemical Engineering, Dalian University of Technology, Panjin, 124221, China
| | - Qing Li
- School of Chemical Engineering, Dalian University of Technology, Panjin, 124221, China
| | - Xiujuan Zhang
- School of Chemical Engineering, Dalian University of Technology, Panjin, 124221, China
| | - Gaohong He
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, 116023, China; School of Chemical Engineering, Dalian University of Technology, Panjin, 124221, China
| | - Shufen Zhang
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, 116023, China
| | - Wenjun Zhang
- School of Chemical Engineering, Dalian University of Technology, Panjin, 124221, China.
| |
Collapse
|
3
|
Yaguchi A, Akahane K, Tsuchioka K, Yonekubo S, Yamamoto S, Tamai Y, Tatemichi S, Takeda H. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study. BMC Nephrol 2019; 20:465. [PMID: 31830936 PMCID: PMC6909506 DOI: 10.1186/s12882-019-1655-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Accepted: 12/03/2019] [Indexed: 02/06/2023] Open
Abstract
Background Approximately 30% of patients on dialysis received combination therapy for their phosphate binder prescription; however, few studies for combined effects of phosphate binders are reported. For the purpose of evaluating the efficacy of combination therapy, we compared the efficacy of sucroferric oxyhydroxide (PA21) combined with calcium carbonate with that of lanthanum carbonate hydrate, sevelamer hydrochloride, and ferric citrate hydrate combined with calcium carbonate. Methods For in vitro studies, calcium carbonate and the other phosphate binders alone or in combination were stirred in phosphate solution at pH 2–8 for 2 h. After centrifuging the suspension, the phosphorus level in the supernatant was determined. For in vivo studies, rats were orally administered calcium carbonate and the other phosphate binders (except for sevelamer hydrochloride) alone or in combination, followed by oral administration of phosphate solution adjusted to pH 2 or 7. Serum samples were collected from the rats at predetermined timepoints and the serum phosphorus levels were determined and analyzed using a two-way analysis of variance. Results In the in vitro study, the measured phosphate-binding capacity of combining sevelamer hydrochloride, PA21, and lanthanum carbonate hydrate with calcium carbonate was approximately equal to or greater than the theoretical values under most conditions. Furthermore, these combined effects were insensitive to pH in that order. The measured phosphate-binding capacity of ferric citrate hydrate combined with calcium carbonate was smaller than the theoretical values, and the combination did not exhibit efficacy under any of the tested conditions. In the in vivo study, the combined effect of PA21 and calcium carbonate at both pH values and that of lanthanum carbonate hydrate and calcium carbonate at pH 2 were additive. In contrast, the combined effect of lanthanum carbonate hydrate and calcium carbonate at pH 7 and that of ferric citrate hydrate and calcium carbonate at pH 2 were antagonistic. Conclusions These results suggest that coadministration of PA21 and calcium carbonate showed good and relatively stable efficacy throughout the range of the gastrointestinal pH and that combining lanthanum carbonate hydrate and ferric citrate hydrate with calcium carbonate may not produce the expected efficacy under certain conditions.
Collapse
Affiliation(s)
- Atsushi Yaguchi
- Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan.
| | - Kenji Akahane
- Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan
| | - Kumi Tsuchioka
- Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan
| | - Saori Yonekubo
- Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan
| | - Shota Yamamoto
- Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan
| | - Yasuaki Tamai
- Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan
| | - Satoshi Tatemichi
- Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan
| | - Hiroo Takeda
- Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan
| |
Collapse
|
4
|
Lin WJ, Lee SA. A novel iron-conjugated acid-modified chitosan derivatives as an oral phosphate binding agent to improve phosphorus adsorption efficacy in vitro and in vivo, synthesis and their characterization. Carbohydr Polym 2019; 212:378-386. [PMID: 30832870 DOI: 10.1016/j.carbpol.2019.02.046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 02/12/2019] [Accepted: 02/14/2019] [Indexed: 01/19/2023]
Abstract
Current phosphate binders used for hyperphosphatemia treatment need large daily dose which make patients' compliance worse and the therapeutic efficacy may not conform the expectation. In this study, three polyacid modified iron-based chitosan derivatives were developed as an oral phosphate binding agent to improve phosphorus adsorption efficacy. The result showed that modification of chitosan by citric acid (CA) could facilitate the conjugation of iron by two folds (272.0 ± 12.1-315.3 ± 20.5 mg Fe/g vs. 141.0 ± 4.9-156.5 ± 8.3 mg Fe/g). All of these iron-based acid-modified chitosan had acceptable safety with cell viability >75% in the concentration up to 250 μg/mL. The stability in terms of iron release in pH 1.0 for 2 h was in the order of DPCS-NAc-CA-Fe (8.9 ± 2.3%) < DPCS-CA-Fe (19.1 ± 4.1%) < DADPCS-CA-Fe (24.6 ± 2.6%) indicating DPCS-NAc-CA-Fe was the most stable one. These iron-based acid-modified chitosan derivatives efficiently adsorbed 255.7 ± 11.3-271.2 ± 19.3 mg of phosphate especially in simulated gastro pH 1.0 in vitro. Furthermore, oral administration of DPCS-NAc-CA-Fe significantly lowered serum phosphorus level from 5.82 ± 0.45 mg/dL to 4.84 ± 0.56 mg/dL (p < 0.01) at 0.25% low feeding dose for 3 weeks without losing of weight, appetite, and activity of Wistar rats.
Collapse
Affiliation(s)
- Wen Jen Lin
- School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Drug Research Center, College of Medicine, National Taiwan University, Taipei, Taiwan.
| | - Shu An Lee
- School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
| |
Collapse
|
5
|
Dietary phosphorus intake estimated by 4-day dietary records and two 24-hour urine collections and their associated factors in Japanese adults. Eur J Clin Nutr 2018; 72:517-525. [PMID: 29500460 DOI: 10.1038/s41430-018-0114-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 09/02/2017] [Accepted: 01/20/2018] [Indexed: 12/17/2022]
Abstract
BACKGROUND/OBJECTIVES Both self-reported dietary information and urinary excretion have limitations in the assessment of phosphorus intake. We conducted a cross-sectional study to estimate dietary phosphorus intake by dietary records (DR) and 24-h urine collections (UC) and examined associated factors. SUBJECTS/METHODS A total of 161 men and 161 women aged 20-69 years completed a 4-day DR and two 24-h UC. Phosphorus intake by UC was estimated using the mean phosphorus absorption rate of 14 papers. Associations between phosphorus intake and urinary excretion and age, body mass index (BMI), physical activity, education, and smoking status were examined using multiple linear regression. RESULTS Phosphorus intake estimated by UC was higher than that estimated by DR (mean: 1393 vs. 1176 mg/day, P < 0.0001 in men; 1082 vs. 1021 mg/day, P = 0.008 in women). Values were significantly correlated (r = 0.29, P = 0.0002 in men; r = 0.30, P = 0.0001 in women). Phosphorus intake estimated by DR was positively associated with age in women. Male current smokers consumed less phosphorus than never smokers. Higher urinary phosphorus excretion was associated with higher BMI in both sexes and higher physical activity in women. CONCLUSIONS This study showed dietary phosphorus intakes estimated by 4-day DR and by 2-day UC in adults. Although dietary phosphorus intake estimated by DR showed moderate correlation with that by UC, they differed in their association with age, BMI, physical activity, and smoking status.
Collapse
|
6
|
Tatemichi S, Nakagaki F, Yoshioka S, Shichiri N. [Pharmacological, pharmaceutical and clinical profiles of sucroferric oxyhydroxide (P-TOL ® Chewable Tab. 250 mg, 500 mg), a therapeutic agent for hyperphosphatemia]. Nihon Yakurigaku Zasshi 2018; 151:75-86. [PMID: 29415929 DOI: 10.1254/fpj.151.75] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Sucroferric oxyhydroxide (P-TOL® chewable tablets, 250 and 500 mg) is a phosphate binder for oral use; it is composed of polynuclear iron (III)-oxyhydroxide, sucrose, and starches, and is currently indicated for alleviating hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The results of non-clinical pharmacological studies have suggested that P-TOL consistently decreases serum phosphorus levels in the aqueous environment at pH levels similar to those in the gastrointestinal tract, thereby suppressing the progression of secondary hyperparathyroidism, aberrant calcification, and abnormal bone metabolism associated with hyperphosphatemia. Since the diameter of the P-TOL tablet exceeds 15 mm, it is manufactured with a doughnut-shape to minimize choking hazards. From the results of pharmaceutical studies, it was indicated that the P-TOL tablets promptly disintegrated in the gastrointestinal tract and excessive iron uptake from this product is unlikely to occur. In clinical studies, P-TOL (one tablet/dose, t.i.d.) decreased serum phosphorus levels during treatment Week 1 and allowed stable, long-term control of serum phosphorus levels. Furthermore, P-TOL was expected to reduce the tablet burden on patients and to improve medication adherence. The most common adverse reaction was diarrhea. However, in most cases, the symptoms were mild and oral administration of P-TOL could be continued. Although iron-related parameters tended to increase, iron uptake from this product was low, and the risk of iron overload was considered to be low. These findings confirm the efficacy and safety of P-TOL in CKD patients with hyperphosphatemia. Therefore, sucroferric oxyhydroxide therapy is a potentially useful treatment option for hyperphosphatemia.
Collapse
Affiliation(s)
- Satoshi Tatemichi
- Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, Kissei Pharmaceutical Co., Ltd
| | - Fumiaki Nakagaki
- Biologics CMC Research and Technology Group, Pharmaceutical Research Laboratory, CMC Research Department, Kissei Pharmaceutical Co., Ltd
| | - Shoichi Yoshioka
- Clinical Development, Clinical Projects Management Section for Biologics Products and LCM Strategy, Clinical Development, Clinical Projects Management Department, Kissei Pharmaceutical Co., Ltd
| | - Natsuko Shichiri
- Clinical Administration, Clinical Research Department, Kissei Pharmaceutical Co., Ltd
| |
Collapse
|
7
|
Abstract
Bone and heart health are linked through a variety of cellular, endocrine, and metabolic mechanisms, including the bidirectional effects of mineral-regulating hormones parathyroid hormone and fibroblast growth factor 23. Nutrition plays an important role in the development of both cardiovascular and bone disease. This review describes current knowledge on the relations between the cardiovascular system and bone and the influence of key nutrients involved in mineral metabolism-calcium, vitamin D, and phosphorus-on heart and bone health, as well as the racial/ethnic differences in cardiovascular disease and osteoporosis and the influence that nutrition has on these disparities.
Collapse
Affiliation(s)
| | - Connie M Weaver
- Department of Nutrition Science, Purdue University, West Lafayette, IN
| | - Dwight A Towler
- Internal Medicine/Endocrine Division, University of Texas Southwestern Medical Center, Dallas, TX; and
| | | | - Regan L Bailey
- Department of Nutrition Science, Purdue University, West Lafayette, IN; Office of Dietary Supplements, National Institutes of Health, Bethesda, MD
| |
Collapse
|
8
|
Nguyen L, Levitt R, Mak RH. Practical Nutrition Management of Children with Chronic Kidney Disease. ACTA ACUST UNITED AC 2016. [DOI: 10.4137/cmu.s13180] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Chronic kidney disease (CKD) introduces a unique set of nutritional challenges for the growing and developing child. This article addresses initial evaluation and ongoing assessment of a child with CKD. It aims to provide an overview of nutritional challenges unique to a pediatric patient with CKD and practical management guidelines. Caloric assessment in children with CKD is critical as many factors contribute to poor caloric intake. Tube feeding is a practical option to provide the required calories and fluid in children who have difficulty with adequate oral intake. Protein intake should not be limited and should be further adjusted for protein loss with dialysis. Supplementation or restriction of sodium is patient specific. Urine output, fluid status, and modality of dialysis are factors that influence sodium balance. Hyperkalemia poses a significant cardiac risk, and potassium is closely monitored. In addition to a low potassium diet, potassium binders may be prescribed to reduce potassium load from oral intake. Phosphorus and calcium play a significant role in cardiovascular and bone health. Phosphorus binders have helped children and families manage phosphorus levels in conjunction with a phosphorus-restricted diet. Nutritional management of children with CKD is a challenge that requires continuous reassessment and readjustment as the child ages, CKD progresses, and urine output decreases.
Collapse
Affiliation(s)
- Lieuko Nguyen
- Division of Nephrology, Department of Pediatrics, Rady Children's Hospital San Diego, University of California, San Diego, La Jolla, CA, USA
| | - Rayna Levitt
- Division of Nephrology, Department of Pediatrics, Rady Children's Hospital San Diego, University of California, San Diego, La Jolla, CA, USA
| | - Robert H. Mak
- Division of Nephrology, Department of Pediatrics, Rady Children's Hospital San Diego, University of California, San Diego, La Jolla, CA, USA
| |
Collapse
|